Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Consensus Recommendation of “Hold” by Analysts

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) has been assigned an average recommendation of “Hold” from the eleven brokerages that are currently covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation and seven have issued a buy recommendation on the company. The average twelve-month target price among brokers that have covered the stock in the last year is $8.8889.

Several research analysts recently commented on IOVA shares. Citigroup reiterated an “outperform” rating on shares of Iovance Biotherapeutics in a research report on Friday, August 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Iovance Biotherapeutics in a report on Thursday, July 2nd. UBS Group boosted their target price on Iovance Biotherapeutics from $4.00 to $7.00 and gave the company a “neutral” rating in a research report on Thursday, August 20th. TD Cowen raised their price target on Iovance Biotherapeutics from $7.00 to $10.00 and gave the stock a “buy” rating in a research report on Monday, August 24th. Finally, Barclays lifted their price objective on shares of Iovance Biotherapeutics from $11.00 to $13.00 and gave the stock an “overweight” rating in a research note on Friday, August 7th.

Iovance Biotherapeutics Stock Down 3.0%

IOVA opened at $8.01 on Tuesday. Iovance Biotherapeutics has a 52 week low of $1.76 and a 52 week high of $9.36. The firm has a 50-day simple moving average of $5.47 and a two-hundred day simple moving average of $4.32. The company has a market capitalization of $3.63 billion, a PE ratio of -10.97 and a beta of 0.71.

Iovance Biotherapeutics (NASDAQ:IOVA) last posted its earnings results on Thursday, August 6th. The biotechnology company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.02. The firm had revenue of $198.63 million for the quarter, compared to the consensus estimate of $87.83 million. Iovance Biotherapeutics had a negative net margin of 89.11% and a negative return on equity of 40.51%. The business’s quarterly revenue was up 65.7% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.33) EPS. As a group, sell-side analysts expect that Iovance Biotherapeutics will post -0.49 earnings per share for the current year.

Hedge Funds Weigh In On Iovance Biotherapeutics

A number of large investors have recently made changes to their positions in the company. KBC Group NV bought a new position in Iovance Biotherapeutics during the 1st quarter valued at about $34,000. Granite Investment Partners LLC bought a new stake in Iovance Biotherapeutics in the fourth quarter worth about $29,000. Motley Fool Asset Management LLC bought a new stake in Iovance Biotherapeutics in the fourth quarter worth about $29,000. Sanctuary Advisors LLC bought a new stake in Iovance Biotherapeutics in the first quarter worth about $38,000. Finally, Fifth Third Bancorp purchased a new position in shares of Iovance Biotherapeutics during the first quarter valued at approximately $39,000. 77.03% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Iovance Biotherapeutics

Here are the key news stories impacting Iovance Biotherapeutics this week:

• Positive Sentiment: Price target raised: Iovance’s price target was increased to $10.00, implying continued upside from recent trading levels and providing a potential catalyst for the stock. Iovance Biotherapeutics Price Target Raised to $10.00
• Positive Sentiment: Some earnings revisions improved: Zacks Research raised its Iovance EPS forecasts for the third quarter of 2026, full-year 2026, second quarter of 2027, second quarter of 2028 and full-year 2028. The FY2026 loss estimate improved from $0.62 to $0.56 per share, while the FY2028 loss estimate improved from $0.10 to $0.07, suggesting expectations for better profitability over time.
• Positive Sentiment: Sector interest: Iovance was highlighted among oncology companies benefiting from continued innovation in cancer treatments. The company’s focus on cell therapy could support investor interest in its commercial and pipeline opportunities. Oncology Stocks to Add to Your Portfolio as Cancer Care Evolves
• Neutral Sentiment: Forecasts remain mixed: Zacks lowered estimates for the first quarter of 2027, third and fourth quarters of 2027, full-year 2027 and first quarter of 2028, including a reduction in the FY2027 loss forecast from $0.36 to $0.44 per share. These cuts offset several of the improved estimates.
• Negative Sentiment: Profitability remains ahead, not immediate: Zacks still expects Iovance to report losses through the forecast period, including estimated losses of $0.56 per share in FY2026 and $0.44 in FY2027. Investors therefore remain dependent on revenue growth, commercial execution and clinical progress rather than near-term profits. Zacks Industry Outlook

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc is a clinical‐stage biotechnology company specializing in the development and commercialization of tumor‐infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company’s lead product candidate, lifileucel (formerly LN‐144), is an autologous TIL therapy in late‐stage clinical development for patients with advanced melanoma. Iovance’s pipeline also includes next‐generation TIL programs such as LN‐145 for cervical and other human papillomavirus (HPV)‐related cancers, as well as exploratory studies in head and neck, non‐small cell lung, gastric and other solid tumor indications.

Iovance’s TIL platform harnesses a patient’s own immune system by isolating, expanding and reinfusing tumor‐reactive lymphocytes.